Similar articles for PMID: 18751370

Year	Number of Results
1998	1
2000	1
2001	5
2002	1
2003	2
2004	3
2005	3
2006	5
2007	12
2008	11
2009	10
2010	8
2011	8
2012	9
2013	1
2014	7
2015	5
2016	1
2017	4
2018	2
2019	5
2020	1
2022	1

1

Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

Siemann DW, Shi W. Siemann DW, et al. Anticancer Res. 2008 Jul-Aug;28(4B):2027-31. Anticancer Res. 2008. PMID: 18751370 Free PMC article.

2

Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.

Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, Pettit GR, Chaplin DJ, Edvardsen K. Hua J, et al. Anticancer Res. 2003 Mar-Apr;23(2B):1433-40. Anticancer Res. 2003. PMID: 12820406

3

Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.

Salmon HW, Mladinich C, Siemann DW. Salmon HW, et al. Eur J Cancer. 2006 Nov;42(17):3073-8. doi: 10.1016/j.ejca.2006.06.016. Epub 2006 Sep 7. Eur J Cancer. 2006. PMID: 16956760

4

Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.

Horsman MR, Wittenborn TR, Nielsen PS, Elming PB. Horsman MR, et al. Int J Mol Sci. 2020 Jul 6;21(13):4778. doi: 10.3390/ijms21134778. Int J Mol Sci. 2020. PMID: 32640548 Free PMC article.

5

Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.

Salmon HW, Siemann DW. Salmon HW, et al. Clin Cancer Res. 2006 Jul 1;12(13):4090-4. doi: 10.1158/1078-0432.CCR-06-0163. Clin Cancer Res. 2006. PMID: 16818709

6

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.

Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, Kerbel RS. Daenen LG, et al. Mol Cancer Ther. 2009 Oct;8(10):2872-81. doi: 10.1158/1535-7163.MCT-09-0583. Mol Cancer Ther. 2009. PMID: 19825805 Free PMC article.

7

Leukemia regression by vascular disruption and antiangiogenic therapy.

Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR. Madlambayan GJ, et al. Blood. 2010 Sep 2;116(9):1539-47. doi: 10.1182/blood-2009-06-230474. Epub 2010 May 14. Blood. 2010. PMID: 20472832 Free PMC article.

8

Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.

Dalal S, Burchill SA. Dalal S, et al. Eur J Cancer. 2009 Mar;45(4):713-22. doi: 10.1016/j.ejca.2008.11.045. Epub 2009 Jan 10. Eur J Cancer. 2009. PMID: 19136249

9

Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.

Eikesdal HP, Sugimoto H, Birrane G, Maeshima Y, Cooke VG, Kieran M, Kalluri R. Eikesdal HP, et al. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15040-5. doi: 10.1073/pnas.0807055105. Epub 2008 Sep 25. Proc Natl Acad Sci U S A. 2008. PMID: 18818312 Free PMC article.

10

From theoretical synergy to clinical supra-additive toxicity.

Soria JC, Massard C, Izzedine H. Soria JC, et al. J Clin Oncol. 2009 Mar 20;27(9):1359-61. doi: 10.1200/JCO.2008.20.8595. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224836 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed